Bayer Pharmaceuticals reveals its strategy on the Egyptian market until 2025

Muhammad Jalal: Efforts to localize 80% of Bayer’s drugs within 5 years…and 40 products, the company’s goals during 2023.

The company received great benefits in the registration of drugs, following the instructions of President El-Sisi

We are working with the Ministry of Health on a £50m public awareness programme

Mohamed Galal, vice president and head of Bayer Middle East’s consumer health department for the pharmaceutical industry, revealed that his company plans to establish a factory in the Egyptian market after launching a large number of drugs that the market needs, in addition to first localizing a few of them in partnership with factories working together with Sadico and Novartis.

Jalal added, in an interview with Amwal Al-Ghad, that there are directives for all parties to provide relief for all pharmaceutical companies to localize the pharmaceutical industry to ensure dollar liquidity and register drugs, with the constant presence of drugs in light of any crisis such as Corona virus outbreak.

He pointed out that the company aims to expand the market by producing 60 to 70% of non-prescription drugs locally by the end of 2025, and also plans to invest 240 million pounds in the Egyptian market to relaunch five new products over the next three years.

Galal pointed out that Bayer is currently planning to work with the Ministry of Health on a new program to educate citizens about several diseases, and the company will pump about 50 million pounds into that program over 3 years…and with the text of the dialogue.

What is Bayer’s plan over the next year in the Egyptian market?

Bayer hopes to increase production capacity in the region in the next few years. Due to rising health awareness and increasing demand, the consumer health industry is expected to expand at an impressive rate.

It is certain that the demand for easily accessible health care will increase as the population grows and the population ages. To ensure equal access to innovative and medical products for all Egyptians, Bayer now works closely with the Egyptian Medicines Authority in coordination with the Unified Public Procurement.

In the last 3 years, the company has also focused on the production of several drugs in the local market, and during the first phase, Bayer managed to localize 5 drugs in Egypt by more than 50%.

Bayer plans to increase the production of raw materials for drugs in the next 5 years, which could reach 80 percent, because it will focus on the production of about 20 new drugs on the Egyptian market, through the Sadico and Novartis factories.

The company also strives to provide medicines that are not widely available in the Egyptian market in cooperation with the Medicines Authority, on top of that there are medicines for heart, allergies, acidity and vitamins.

Bayer Middle East is currently working to transfer the latest technology to Egypt to facilitate the local production of raw materials.

Bayer Pharmaceutical Company intends to invest EGP 240 million in the Egyptian market to relaunch five new products in the local market over the next three years.

The company’s goal is to expand the market by producing 60% to 70% of over-the-counter medicines at the local level by the end of 2025.

Is Bayer planning to establish a drug factory in Egypt?

During the current period, we are studying the idea of ​​establishing a pharmaceutical factory in the Egyptian market, but the idea will not materialize after the launch of many products in the market.

Bayer has so far offered about 22 medicines in Egypt, and plans to reach 40 medicines by the end of next year.

What is Bayer’s plan to export abroad via Egypt?

Bayer intends to penetrate several countries in the Middle East through the Egyptian market once it is self-sufficient in the local market, and the company has an ambitious export pipeline to some European countries within two to three years.

What is Bayer’s market share in Egypt?

The company’s market share during the current period in the Egyptian market has reached about 2%, and we aim to reach 3% during the next 3 years.

Has the group reduced the number of workers in the Middle East?

In 2018, Bayer International developed a plan to lay off 12,000 workers at the group level to reduce costs, as the largest percentage of laid off workers were in Germany, but in the Middle East, the percentage of workers increased from 15 to 20% in the last 4 years.

What is the target company’s sales volume by the end of 2022?

Bayer aims to achieve sales on the Egyptian market of around EUR 40 million, and the group achieved global net sales of EUR 12.8 billion during the second quarter of this year.

The group’s sales amounted to 44.1 billion euros in 2021, and the group’s investments last year amounted to around 5 billion euros.

Did Bayer get relief in the registration of medicines on the orders of President El-Sisi?

Bayer received major benefits from Egypt’s Medicines Authority to quickly register all drugs, as the country has clear instructions from President El-Sisi to support all pharmaceutical companies.

dr. Hossam Abdel Ghaffar, spokesman for the Ministry of Health and Population, confirmed that there are ongoing instructions from President Abdel Fattah El-Sisi to work on the localization of the pharmaceutical industry, pointing out that the Corona pandemic has revealed that countries that do not have production capacity have suffered during the Corona pandemic.

President Abdel Fattah El-Sisi also ordered the acceleration of executive steps to establish strategic warehouses for medical storage at the level of the Republic. With the aim of ensuring the ability to provide a strategic reserve to cover the needs of current and future consumption of medical supplies and medicines, in accordance with international standards, with the use of the latest technological means, while ensuring the sustainability factors of effective management and operations.

Does Bayer cooperate with the Ministry of Health in awareness campaigns?

In recent years, Bayer has collaborated with the Ministry of Health in several initiatives, the most significant of which are 100 million health and early disease detection, in addition, the company is currently planning to work with the Ministry on a new program for educating citizens about several diseases.

The company will invest around £50 million in the program over 3 years.

Bayer has also entered into agreements with some local and international companies operating in the Egyptian market, with the aim of providing Egyptian patients with access to the latest innovations in consumer health.

What mechanisms support the growth of the pharmaceutical sector in Egypt?

Egypt’s pharmaceutical sector has witnessed some of the highest growth rates in the Middle East, and the industrial sector is considered one of the important pillars of Egypt’s economic reform strategy, greatly advancing the sustainable development goals of the country’s Vision 2030. As a result, our comprehensive three-year strategy aims to grow the company’s business in the Egyptian market.

With the recent growth of elevit, we have seen part of this strategy take shape and is a testament to Bayer’s commitment to ensuring access to nutrition for Egyptian mothers, raising awareness of the value of proper nutrition and improving maternal health and quality of life worldwide. world.

Bayer is also focused on raising awareness and preventing serious health problems to reduce the burden on healthcare organizations. For potential expansion into regional markets, including the Egyptian market, healthcare personalization is key.

What about a product from the recently expanded Elevate line?

Bayer introduces elevit® Pregnancy and elevit® Breastfeeding, two new multivitamin and mineral supplements designed to support maternal nutritional health and infant development. Bayer recently expanded its portfolio of prenatal-based multivitamins in Egypt.

In order to ensure adequate supply of the nutritional needs of mothers at every stage of the first 1000 days of the child’s life, the range includes a number of important nutrients and vitamins, including folic acid, iron, omega-3 / DHA, vitamin D, vitamin C and vitamins of the B group.